Calorie Restriction Mimetics / AntiCan Cancer Research Results

CRMs, Calorie Restriction Mimetics: Click to Expand ⟱
Features:
Caloric restriction mimetics (CRMs)

Examples of the most studied CRM and their anti-cancer effects include metformin, rapamycin, aspirin, and resveratrol and its by-products.

Calorie Restriction Mimetics — Calorie restriction mimetics (CRMs) are a mechanistic class of compounds intended to reproduce selected biochemical effects of caloric restriction without requiring sustained energy restriction. They are best viewed as a research/therapeutic concept rather than a single drug entity or a formally approved regulatory class. Standard abbreviation: CRM or CRMs. In the oncology literature, the most commonly cited CRMs are metformin, rapamycin or rapalogs, aspirin or salicylate, resveratrol, spermidine, and hydroxycitrate; broader candidate lists often also include EP300-inhibitory or sirtuin-linked dietary compounds such as curcumin, garcinol, anacardic acid, EGCG, and some synthetic sirtuin activators. Their shared functional identity is partial imitation of nutrient-deprivation signaling, especially autophagy induction, lowered protein acetylation, AMPK-SIRT engagement, and relative suppression of anabolic growth signaling. In practice, however, CRM biology is highly heterogeneous, agent-specific, and often limited by pharmacokinetics, dose ceilings, or context-dependent tumor effects.

Primary mechanisms (ranked):

  1. Autophagy induction and proteostasis remodeling, often via reduced cytosolic acetyl-CoA signaling and lower global protein acetylation
  2. AMPK activation with downstream suppression of PI3K-AKT-mTOR growth signaling and reduced anabolic drive
  3. EP300 acetyltransferase inhibition or functional opposition, promoting deacetylation-linked fasting-like signaling
  4. Sirtuin-linked stress adaptation and mitochondrial remodeling, especially with resveratrol-like or NAD-related CRM candidates
  5. Systemic insulin-glucose-IGF axis attenuation, reducing nutrient availability and mitogenic support for susceptible tumors
  6. Immune-context effects, including improved chemotherapy responsiveness and, in some models, enhanced anticancer immunosurveillance
  7. Secondary anti-inflammatory and HIF-1α-glycolysis dampening effects in subsets of CRMs

Bioavailability / PK relevance: PK is not class-uniform. Metformin is orally available but hydrophilic and tissue-distribution dependent; rapamycin is orally active but shows variable exposure and clinically important immunosuppressive toxicity; aspirin is systemically available but dose-limited by bleeding risk; resveratrol has poor oral bioavailability and rapid metabolism; spermidine supplementation can show only modest increases in circulating polyamines because of strong homeostatic control. Many “dietary CRM” candidates therefore have more convincing mechanistic than translational PK support.

In-vitro vs systemic exposure relevance: This is a major translation issue for the class. Many in-vitro CRM studies use concentrations that are not cleanly achievable in human plasma or tumors, especially for metformin and several polyphenols such as resveratrol. Accordingly, class-level conclusions should prioritize pathway directionality and combination/adjunct effects over direct cytotoxicity observed at high in-vitro doses.

Clinical evidence status: Mixed and agent-dependent. For cancer, CRM evidence is strongest at the preclinical and adjunct-mechanistic level. Human data exist mainly for individual agents such as metformin, aspirin, and rapalogs rather than for “CRMs” as a validated class, and results remain heterogeneous across tumor types and trial designs. At present, CRMs are better regarded as a translational framework and combination strategy than as an established standalone oncology therapy category.

CRM Product/Priority Table

Tier Priority Agent CRM Strength Main Rationale Comments
1 1 Spermidine Very strong Among the cleanest strict CRMs; promotes autophagy and opposes protein acetylation through EP300-related mechanisms Best fit for a mechanistically strict CRM
1 2 Hydroxycitrate Very strong Strong strict CRM; reduces acetyl-CoA availability, lowers protein acetylation, and induces autophagy Also has notable anticancer adjunct evidence
1 3 Aspirin/ salicylate Strong Can inhibit EP300 and induce fasting-like autophagy signaling Good translational relevance compared with many dietary CRMs
2 4 Metformin Strong but indirect Major CRM-associated drug due to AMPK activation, reduced anabolic signaling, and host metabolic effects Important in oncology, though less strict mechanistically than tier 1
2 5 Rapamycin / rapalogs Strong but indirect Suppresses mTOR and reproduces part of the nutrient-deprivation program Highly important, but more targeted than classic acetylation-centered CRMs
2 6 Resveratrol Moderate to strong Historically prominent due to SIRT1-linked and autophagy-related fasting-like signaling Limited by weak pharmacokinetics and broader mechanistic ambiguity
3 7 EGCG Moderate Often included as a putative CRM because it can affect acetyltransferase activity and autophagy-related signaling Less central than higher-tier agents
3 8 Curcumin Moderate Frequently listed as a CRM-like dietary compound through acetylation and autophagy-related effects Not a class-defining CRM
3 9 Garcinol Moderate Mechanistically interesting EP300-related candidate Mostly preclinical and less developed clinically
3 10 Anacardic acid Moderate Acetyltransferase-inhibitory CRM candidate Mainly mechanistic and preclinical
4 11 Acarbose Plausible but broad Blunts postprandial glucose and nutrient signaling More of a systemic metabolic mimic than a strict autophagy-centered CRM
4 12 Glucosamine Plausible but weak Sometimes classified as a CRM-like metabolic agent Cancer-specific relevance is much weaker
4 13 Nicotinamide / nicotinamide riboside / other NAD-linked agents Debatable Occasionally placed in broad CRM lists Less standardized as oncology CRMs

Mechanistic Pathway Table

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 Autophagy induction ↑ autophagic flux; may reduce growth fitness, stress tolerance mismatch, or therapy resistance ↑ stress adaptation, proteostasis, organelle quality control Core fasting-like reprogramming This is the most coherent class-defining mechanism across stricter CRMs. In cancer, benefit is context-dependent because autophagy can also support survival in some settings.
2 AMPK activation ↑ energy stress signaling; proliferation programs ↓ ↑ metabolic efficiency and adaptive stress signaling Nutrient-sensing reset Especially relevant for metformin-like CRMs; often linked secondarily to mTOR suppression and lower biosynthetic drive.
3 mTORC1 anabolic signaling ↓ protein synthesis, cell growth, and proliferation ↓ excessive anabolism; may support maintenance programs Antiproliferative restraint Rapamycin and rapalogs act most directly here. This axis has strong industry relevance because it is already druggable and clinically validated in oncology for specific agents.
4 EP300 acetyltransferase and protein acetylation ↓ protein acetylation; fasting-like deacetylation programs ↑ ↓ acetylation tone; autophagy competence ↑ Autophagy-permissive deacetylation Hydroxycitrate acts upstream through acetyl-CoA depletion; spermidine and salicylate can oppose EP300 activity more directly. This is a key stricter CRM-defining axis.
5 Acetyl-CoA supply and citrate-ACLY axis ↓ lipogenic and acetylation-supportive substrate availability ↓ anabolic surplus signaling Metabolic substrate restriction Most class-relevant for hydroxycitrate-like CRMs. Mechanistically central in strict CRM literature, but less clinically deployed than AMPK-mTOR agents.
6 Sirtuin signaling and NAD-linked stress adaptation ↑ stress-response remodeling; growth signaling ↓ (context-dependent) ↑ mitochondrial maintenance and stress resilience CR-like adaptive signaling Most associated with resveratrol and synthetic sirtuin activators. Mechanistically plausible, but human translational strength is weaker than for metformin or rapamycin.
7 Insulin glucose IGF signaling ↓ nutrient-driven mitogenic support Improved insulin sensitivity and metabolic control Systemic host-level antitumor pressure Important because some CRM benefits may be host-mediated rather than directly tumoricidal. Likely most relevant in hyperinsulinemic or metabolically dysregulated settings.
8 Mitochondrial energetics and OXPHOS stress ↓ mitochondrial energy throughput or biosynthetic support (agent-dependent) Adaptive remodeling more likely than outright injury at therapeutic exposure Bioenergetic constraint Metformin-like CRMs can stress complex I-linked metabolism, but many direct mitochondrial effects reported in vitro occur at supra-clinical concentrations.
9 HIF-1α glycolysis axis ↓ hypoxia-adaptive and glycolytic signaling (secondary, context-dependent) Usually limited or indirect effect Secondary metabolic suppression This is not universal across CRMs, but often appears downstream of AMPK-mTOR and lower anabolic signaling.
10 Inflammation COX prostaglandin signaling Inflammatory support programs ↓ Inflammation tone ↓ Microenvironmental restraint Most relevant to aspirin or salicylate-containing CRM interpretations. Important clinically, but not a universal class-defining axis.
11 Chemosensitization and anticancer immunity Therapy responsiveness ↑ in selected models Normal-tissue stress tolerance may improve (context-dependent) Adjunct therapeutic leverage Preclinical work with hydroxycitrate and spermidine suggests improved chemotherapy efficacy and altered tumor immune contexture, but this remains incompletely validated in human oncology.
12 Clinical Translation Constraint Heterogeneous exposure-response; tumor context strongly modifies benefit Host toxicity and metabolic background shape tolerability Limits class-wide deployment The CRM concept is stronger than the class-level clinical evidence. Main constraints are nonuniform PK, supra-physiologic in-vitro dosing, immunosuppression for rapamycin-class agents, bleeding for aspirin, renal/lactic-acidosis concerns for metformin, and weak systemic exposure for several dietary polyphenols.


AntiCan, Anticancer Effect: Click to Expand ⟱
Source:
Type: general indicator
Anticancer Effect


Scientific Papers found: Click to Expand⟱
5780- CRMs,  HCAs,  RES,  Sper,  ASA  Caloric Restriction Mimetics against Age-Associated Disease: Targets, Mechanisms, and Therapeutic Potential
- Review, Var, NA
*OS↑, *AntiAge↑, *cardioP↑, *neuroP↑, AntiCan↑, *TNF-α↓, *Weight↓, *BP↓, *Inflam↓, *Insulin↓, *ROS↓, *AMPK↑, *mTOR↓, *SIRT1↑, CRM↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

CRM↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,  
Total Targets: 2

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Mitochondria & Bioenergetics ⓘ

Insulin↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   SIRT1↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

BP↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   cardioP↑, 1,   neuroP↑, 1,   OS↑, 1,   Weight↓, 1,  
Total Targets: 13

Scientific Paper Hit Count for: AntiCan, Anticancer Effect
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:284  Target#:813  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page